Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 10
Submit an article Journal homepage
1,198
Views
125
CrossRef citations to date
0
Altmetric
Drug Evaluations

Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

David B Henley Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer's Team, DC 6161, Indianapolis, IN 46285-6161, USA +1 317 433 9573; +1 317 433 0448; [email protected]
, MD,
Patrick C May Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer's Team, DC 6161, Indianapolis, IN 46285-6161, USA +1 317 433 9573; +1 317 433 0448; [email protected]
, PhD,
Robert A Dean Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer's Team, DC 6161, Indianapolis, IN 46285-6161, USA +1 317 433 9573; +1 317 433 0448; [email protected]
, MD PhD &
Eric R Siemers Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer's Team, DC 6161, Indianapolis, IN 46285-6161, USA +1 317 433 9573; +1 317 433 0448; [email protected]
, MD
Pages 1657-1664 | Published online: 15 Jun 2009

Citations (125)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Ritu Jain, Janakiraman Subramanian & Anurag S. Rathore. (2023) A review of therapeutic failures in late-stage clinical trials. Expert Opinion on Pharmacotherapy 24:3, pages 389-399.
Read now
Bob Olsson, Jonathan M. Schott, Kaj Blennow & Henrik Zetterberg. (2017) The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials. Expert Review of Neurotherapeutics 17:8, pages 767-775.
Read now
Chris G. Parsons & Gerhard Rammes. (2017) Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease. Expert Opinion on Investigational Drugs 26:5, pages 579-592.
Read now
Gabriel C Léger & Fadi Massoud. (2013) Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 6:4, pages 423-442.
Read now
Jianxun Han & Qiang Shen. (2012) Targeting γ-secretase in breast cancer. Breast Cancer: Targets and Therapy 4, pages 83-90.
Read now
Anne Corbett & Clive Ballard. (2012) New and emerging treatments for Alzheimer's disease. Expert Opinion on Emerging Drugs 17:2, pages 147-156.
Read now
Anne Corbett, Jessica Smith & Clive Ballard. (2012) New and emerging treatments for Alzheimer’s disease. Expert Review of Neurotherapeutics 12:5, pages 535-543.
Read now
Chihiro Tohda, Rie Nakada, Takuya Urano, Akira Okonogi & Tomoharu Kuboyama. (2011) Kamikihi-to (KKT) Rescues Axonal and Synaptic Degeneration Associated with Memory Impairment in a Mouse Model of Alzheimer's Disease, 5XFAD. International Journal of Neuroscience 121:12, pages 641-648.
Read now
Eri Joyashiki, Yuji Matsuya & Chihiro Tohda. (2011) Sominone Improves Memory Impairments and Increases Axonal Density in Alzheimer's Disease Model Mice, 5XFAD. International Journal of Neuroscience 121:4, pages 181-190.
Read now
Weiming Xia. (2010) Brain amyloid β protein and memory disruption in Alzheimer’s disease. Neuropsychiatric Disease and Treatment 6, pages 605-611.
Read now

Articles from other publishers (115)

Ritesh P. Bhole, Rupesh V. Chikhale & Karishma M. Rathi. (2023) Current Biomarkers and Treatment Strategies in Alzheimer Disease: An Overview and Future Perspectives. IBRO Neuroscience Reports.
Crossref
Snehal Raut, Aditya Bhalerao, Michael Powers, Minelly Gonzalez, Salvatore Mancuso & Luca Cucullo. (2023) Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview. Cells 12:16, pages 2019.
Crossref
Eszter K. Vladar, Koshi Kunimoto, Laura S. Rojas-Hernandez, Jacquelyn M. Spano, Zachary M. Sellers, Nam Soo Joo, Riley A. Cooney, Jeffrey D. Axelrod & Carlos E. Milla. (2023) Notch signaling inactivation by small molecule γ-secretase inhibitors restores the multiciliated cell population in the airway epithelium. American Journal of Physiology-Lung Cellular and Molecular Physiology 324:6, pages L771-L782.
Crossref
GS Meghana, DV Gowda, Saravana Babu Chidambaram & Riyaz Ali Osmani. (2023) Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach. Vibrational Spectroscopy 126, pages 103510.
Crossref
Weiwei Yao, Huihui Yang & Jinfei Yang. (2022) Small-molecule drugs development for Alzheimer's disease. Frontiers in Aging Neuroscience 14.
Crossref
Ekta Shirbhate, Vijay K. Patel, Priya Tiwari, Rakesh Kore, Ravichandran Veerasamy, Achal Mishra & Harish Rajak. (2022) Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects. Current Topics in Medicinal Chemistry 22:22, pages 1849-1867.
Crossref
Yuxuan Dai, Chenyi Lei, Zhenhao Zhang, Yan Qi, Kejing Lao & Xingchun Gou. (2022) Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead. Current Drug Targets 23:11, pages 1040-1056.
Crossref
Jijian Gao, Peng Wu, Yingjun Chi, Hongyu Xu, Yong Zhao, Nanyan Song & Yuanqing Mao. (2022) LY450139 Inhibited Ti-Particle-Induced Bone Dissolution via Suppressing Notch and NF-κB Signaling Pathways. Calcified Tissue International 111:2, pages 211-223.
Crossref
Jiachen Wen, Dan Liu & Linxiang Zhao. (2022) Small molecules targeting γ-secretase and their potential biological applications. European Journal of Medicinal Chemistry 232, pages 114169.
Crossref
Lei Guo, Margaret B. Zhong, Larry Zhang, Bin Zhang & Dongming Cai. (2022) Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape. Biological Psychiatry 91:1, pages 61-71.
Crossref
Hang Zhao, Xuerong Huang & Zhiqian Tong. (2021) Formaldehyde‐Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives. ChemMedChem 16:22, pages 3376-3390.
Crossref
Sedigheh Eskandari, Soraya Sajadimajd, Loghman Alaei, Zhaleh Soheilikhah, Hossein Derakhshankhah & Gholamreza Bahrami. (2021) Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer’s: a Comprehensive Review. Neurotoxicity Research 39:5, pages 1589-1612.
Crossref
Željko M. Svedružić, Katarina Vrbnjak, Manuel Martinović & Vedran Miletić. (2021) Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer’s Disease. Pharmaceutics 13:4, pages 514.
Crossref
Ankit Tandon, Sangh J. Singh & Rajnish K. Chaturvedi. (2021) Nanomedicine against Alzheimer’s and Parkinson’s Disease. Current Pharmaceutical Design 27:12, pages 1507-1545.
Crossref
Luis O. Soto-Rojas, Mar Pacheco-Herrero, Paola A. Martínez-Gómez, B. Berenice Campa-Córdoba, Ricardo Apátiga-Pérez, Marcos M. Villegas-Rojas, Charles R. Harrington, Fidel de la Cruz, Linda Garcés-Ramírez & José Luna-Muñoz. (2021) The Neurovascular Unit Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences 22:4, pages 2022.
Crossref
Hariharan Moorthy & Thimmaiah Govindaraju. (2021) Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine. ACS Applied Bio Materials 4:2, pages 1115-1139.
Crossref
Guanghui Yang, Rui Zhou, Xuefei Guo, Chuangye Yan, Jianlin Lei & Yigong Shi. (2021) Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell 184:2, pages 521-533.e14.
Crossref
Vipul Chaudhary, Ashwini Kumar Nigam, Ashutosh Paliwal, Manoj Kumar Singh, Jalaj Kumar Gour & Vimlendu Bhushan Sinha. 2021. Naturally Occurring Chemicals Against Alzheimer's Disease. Naturally Occurring Chemicals Against Alzheimer's Disease 65 82 .
Chuan-cong Zhu, Si-yu Fu, Yu-xin Chen, Ling Li, Ruo-lin Mao, Jian-zhi Wang, Rong Liu, Yi Liu & Xiao-chuan Wang. (2021) Advances in Drug Therapy for Alzheimer’s Disease. Current Medical Science 40:6, pages 999-1008.
Crossref
Md. Sahab Uddin, Md. Tanvir Kabir, Md. Sohanur Rahman, Tapan Behl, Philippe Jeandet, Ghulam Md Ashraf, Agnieszka Najda, May N. Bin-Jumah, Hesham R. El-Seedi & Mohamed M. Abdel-Daim. (2020) Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease. International Journal of Molecular Sciences 21:16, pages 5858.
Crossref
Matan B. Abou, Liang Sun & Huafeng Wei. (2020) Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease. Current Alzheimer Research 17:4, pages 324-328.
Crossref
Maruti J. Dhanavade & Kailas D. Sonawane. (2020) Amyloid beta peptide-degrading microbial enzymes and its implication in drug design. 3 Biotech 10:6.
Crossref
Md. Tanvir Kabir, Md. Sahab Uddin, Abdullah Al Mamun, Philippe Jeandet, Lotfi Aleya, Rasha A. Mansouri, Ghulam Md Ashraf, Bijo Mathew, May N. Bin-Jumah & Mohamed M. Abdel-Daim. (2020) Combination Drug Therapy for the Management of Alzheimer’s Disease. International Journal of Molecular Sciences 21:9, pages 3272.
Crossref
Peter S.B. Finnie & Karim Nader. (2020) Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. Current Biology 30:10, pages 1934-1940.e4.
Crossref
Xiaokang Li, Jian Lu, Yixiang Xu, Jiaying Wang, Xiaoxia Qiu, Lei Fan, Baoli Li, Wenwen Liu, Fei Mao, Jin Zhu, Xu Shen & Jian Li. (2020) Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease. Acta Pharmaceutica Sinica B 10:4, pages 646-666.
Crossref
Carla Garcia-Mazas, Sheila Barrios-Esteban, Noemi Csaba & Marcos Garcia-Fuentes. 2020. Biomaterials for Cancer Therapeutics. Biomaterials for Cancer Therapeutics 365 398 .
Safikur Rahman, Manali Datta, Jihoe Kim & Arif Tasleem Jan. (2019) CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases. Seminars in Cell & Developmental Biology 96, pages 22-31.
Crossref
Anjana Sinha, Katherina Gindinova, Emily Mui, William J. Netzer & Subhash C. Sinha. (2019) Development of Kinase Inactive PD173955 Analogues for Reducing Production of Aβ Peptides. ACS Medicinal Chemistry Letters 10:10, pages 1430-1435.
Crossref
Carlos A. Toro, Larry Zhang, Jiqing Cao & Dongming Cai. (2019) Sex differences in Alzheimer’s disease: Understanding the molecular impact. Brain Research 1719, pages 194-207.
Crossref
Meer Asif Ali, Sugunakar Vuree, Himshikha Goud, Tajamul Hussain, Anuraj Nayarisseri & Sanjeev Kumar Singh. (2019) Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer’s Disease. Current Topics in Medicinal Chemistry 19:13, pages 1173-1187.
Crossref
Hathout Rania M, Ehab Ammar, Ibrahim Mohamed, Magdi Marel, Ayman Mohamed, Zidan Nourhan, Osman Abdelbaset, Ashraf Sara, Mohamed Mayar, Magdy Mirna, Hany Marina, Adly Marise, Kamel Nourhan, Maher Amr, Yaser Ammar, Ahmed Yara, Abdelkarim Amal, Ehab Marehan & Wael Rana. (2019) Alzheimer’s disease and its current treatments; Is there a possibility for a cure?. Open Journal of Chemistry 5:1, pages 013-019.
Crossref
Prashant Bharadwaj. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease 291 310 .
Lídia Pinheiro & Célia Faustino. (2019) Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease. Current Alzheimer Research 16:5, pages 418-452.
Crossref
Piyoosh Sharma, Pavan Srivastava, Ankit Seth, Prabhash Nath Tripathi, Anupam G. Banerjee & Sushant K. Shrivastava. (2019) Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Progress in Neurobiology 174, pages 53-89.
Crossref
Rui Zhou, Guanghui Yang, Xuefei Guo, Qiang ZhouJianlin Lei & Yigong Shi. (2019) Recognition of the amyloid precursor protein by human γ-secretase. Science 363:6428.
Crossref
Kevin Mullane & Michael Williams. (2019) The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. Current Opinion in Pharmacology 44, pages 62-75.
Crossref
Benjamin Chun-Kit Tong, Aston Jiaxi Wu, Min Li & King-Ho Cheung. (2018) Calcium signaling in Alzheimer's disease & therapies. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1865:11, pages 1745-1760.
Crossref
Fan Huang, Aoting Qu, Huiru Yang, Lin Zhu, Hao Zhou, Jianfeng Liu, Jiafu Long & Linqi Shi. (2018) Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid β Peptide Associated with Alzheimer’s Disease. ACS Macro Letters 7:8, pages 983-989.
Crossref
Maria Teresa Ferretti, Maria Florencia Iulita, Enrica Cavedo, Patrizia Andrea Chiesa, Annemarie Schumacher Dimech, Antonella Santuccione Chadha, Francesca Baracchi, Hélène Girouard, Sabina Misoch, Ezio Giacobini, Herman Depypere & Harald Hampel. (2018) Sex differences in Alzheimer disease — the gateway to precision medicine. Nature Reviews Neurology 14:8, pages 457-469.
Crossref
Frank J Simutis, Thomas P Sanderson, Gary D Pilcher & Michael J Graziano. (2018) Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat. Toxicological Sciences 163:2, pages 525-542.
Crossref
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, Norbert Benda, Karl Broich, A. Claudio Cuello, Jeffrey Cummings, Bruno Dubois, Howard J. Federoff, Massimo Fiandaca, Remy Genthon, Marion Haberkamp, Eric Karran, Mark Mapstone, George Perry, Lon S. Schneider, Lindsay A. Welikovitch, Janet Woodcock, Filippo Baldacci & Simone Lista. (2018) Precision pharmacology for Alzheimer’s disease. Pharmacological Research 130, pages 331-365.
Crossref
Devendra Kumar, Ankit Ganeshpurkar, Dileep Kumar, Gyan Modi, Sanjeev Kumar Gupta & Sushil Kumar Singh. (2018) Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. European Journal of Medicinal Chemistry 148, pages 436-452.
Crossref
Ja-Young Jang, Hyangshuk Rhim & Seongman Kang. (2018) NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - General Subjects 1862:1, pages 71-80.
Crossref
Torben Mentrup, Ann-Christine Loock, Regina Fluhrer & Bernd Schröder. (2017) Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets?. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864:11, pages 2169-2182.
Crossref
T Karelina, O Demin, T Nicholas, Y Lu, S Duvvuri & HA Barton. (2017) A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human. CPT: Pharmacometrics & Systems Pharmacology 6:10, pages 666-675.
Crossref
Md. Rashidur Rahman, Afsana Tajmim, Mohammad Ali & Mostakim Sharif. (2017) Overview and Current Status of Alzheimer’s Disease in Bangladesh. Journal of Alzheimer's Disease Reports 1:1, pages 27-42.
Crossref
Zhidong Liu, Aihua Zhang, Hui Sun, Ying Han, Ling Kong & Xijun Wang. (2017) Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances 7:10, pages 6046-6058.
Crossref
A.O. Adeniji, P.W. Adams & V.V. Mody. 2017. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders 109 143 .
Mikko Hölttä, Robert A. Dean, Eric Siemers, Kwasi G. Mawuenyega, Wendy Sigurdson, Patrick C. May, David M. Holtzman, Erik Portelius, Henrik Zetterberg, Randall J. Bateman, Kaj Blennow & Johan Gobom. (2016) A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research & Therapy 8:1.
Crossref
Rajesh Kumar, Lucienne Juillerat-Jeanneret & Dela Golshayan. (2016) Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases. Journal of Medicinal Chemistry 59:17, pages 7719-7737.
Crossref
Robert Briggs, Sean P Kennelly & Desmond O'Neill. (2016) Drug treatments in Alzheimer’s disease. Clinical Medicine 16:3, pages 247-253.
Crossref
Genevieve Evin. (2016) Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors. BioDrugs 30:3, pages 173-194.
Crossref
Hosakere N Ravishankar, Abhik Dutta, Alisha G Lewis & Amogh Mohan. (2016) Advances in therapies and scope for personalized medicine in Alzheimer's disease. Personalized Medicine 13:2, pages 189-199.
Crossref
Manika Awasthi, Swati Singh, Veda P. Pandey & Upendra N. Dwivedi. (2016) Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. Journal of the Neurological Sciences 361, pages 256-271.
Crossref
Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case, Gopalan Sethuraman, Hong Liu‐Seifert, Sherie A. Dowsett, Michael J. Pontecorvo, Robert A. Dean & Ronald Demattos. (2015) Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimer's & Dementia 12:2, pages 110-120.
Crossref
Maximilian Pohland, Stephanie Hagl, Maren Pellowska, Mario Wurglics, Manfred Schubert-Zsilavecz & Gunter P. Eckert. (2015) MH84: A Novel γ-Secretase Modulator/PPARγ Agonist—Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer’s Disease. Neurochemical Research 41:1-2, pages 231-242.
Crossref
Eun-Kyoung KohWoo-Bin YunJi-Eun KimSung-Hwa SongJi-Eun SungHyun-Ah LeeEun-Ji SeoSeung-Wan JeeChang-Joon BaeDae-Youn Hwang. (2016) Beneficial effect of diosgenin as a stimulator of NGF on the brain with neuronal damage induced by Aβ-42 accumulation and neurotoxicant injection. Laboratory Animal Research 32:2, pages 105.
Crossref
Chihiro Tohda. (2016) New Age Therapy for Alzheimer’s Disease by Neuronal Network Reconstruction. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 39:10, pages 1569-1575.
Crossref
Joshua D Grill, Rema Raman, Karin Ernstrom, Paul Aisen, Sherie A Dowsett, Yun-Fei Chen, Hong Liu-Seifert, Ann Marie Hake, David S Miller, Rachelle S Doody, David B Henley & Jeffrey L Cummings. (2015) Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials. Alzheimer's Research & Therapy 7:1.
Crossref
Zhiqiang Zhao, Dmitri A. Pissarnitski, Hubert B. Josien, Wen-Lian Wu, Ruo Xu, Hongmei Li, John W. Clader, Duane A. Burnett, Giuseppe Terracina, Lynn Hyde, Julie Lee, Lixin Song, Lili Zhang & Eric M. Parker. (2015) Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors. Journal of Medicinal Chemistry 58:22, pages 8806-8817.
Crossref
Jaspreet Kalra & Aamir Khan. (2015) Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. European Journal of Pharmacology 764, pages 571-581.
Crossref
Tianhan Kai, Lin Zhang, Xiaoying Wang, Aihua Jing, Bingqing Zhao, Xiang Yu, Jie Zheng & Feimeng Zhou. (2015) Tabersonine Inhibits Amyloid Fibril Formation and Cytotoxicity of Aβ(1–42). ACS Chemical Neuroscience 6:6, pages 879-888.
Crossref
Andreas Soejitno, Anastasia Tjan & Thomas Eko Purwata. (2015) Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs 29:6, pages 487-502.
Crossref
Cuicui Wang, Jie Shen, Kiminori Yukata, Jason A. Inzana, Regis J. O'Keefe, Hani A. Awad & Matthew J. Hilton. (2015) Transient gamma-secretase inhibition accelerates and enhances fracture repair likely via Notch signaling modulation. Bone 73, pages 77-89.
Crossref
Alena V. Savonenko, Tatiana Melnikova, Tong Li, Donald L. Price & Philip C. Wong. 2015. Neurobiology of Brain Disorders. Neurobiology of Brain Disorders 321 338 .
Kieren Egan & Malcolm Macleod. (2014) Two decades testing interventions in transgenic mouse models of Alzheimer's disease: designing and interpreting studies for clinical trial success. Clinical Investigation 4:8, pages 693-704.
Crossref
Eric Karran & John Hardy. (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annals of Neurology 76:2, pages 185-205.
Crossref
S. Beggiato, A. Giuliani, S. Sivilia, L. Lorenzini, T. Antonelli, B.P. Imbimbo, L. Giardino, L. Calzà & L. Ferraro. (2014) CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience 266, pages 13-22.
Crossref
D. I. Rodin, A. L. Schvarzman & S. V. Saranzeva. (2014) Modern approach in the therapy of Alzheimer's disease. The Scientific Notes of the I. P. Pavlov St. Petersburg State Medical University 21:1, pages 6-10.
Crossref
J. A. Mikulca, V. Nguyen, D. A. Gajdosik, S. G. Teklu, E. A. Giunta, E. A. Lessa, C. H. Tran, E. C. Terak & R. B. Raffa. (2014) Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. Journal of Clinical Pharmacy and Therapeutics 39:1, pages 25-37.
Crossref
Sun-Ho HanInhee Mook-Jung. (2014) Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science 29:7, pages 893.
Crossref
Qiutian Jia, Yulin Deng & Hong Qing. (2014) Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyond β -Amyloid: Insights from Clinical Trials . BioMed Research International 2014, pages 1-22.
Crossref
Umer Rashid & Farzana L. Ansari. 2014. Drug Design and Discovery in Alzheimer's Disease. Drug Design and Discovery in Alzheimer's Disease 40 141 .
Xuan Ye, Wenjiao Tai, Xiuqi Bao, Xiaoguang Chen & Dan Zhang. (2013) FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells. Naunyn-Schmiedeberg's Archives of Pharmacology 387:1, pages 75-85.
Crossref
Ezio Giacobini & Gabriel Gold. (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nature Reviews Neurology 9:12, pages 677-686.
Crossref
Patrick L. McGeer & Edith G. McGeer. (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathologica 126:4, pages 479-497.
Crossref
Gary Probst, Danielle L. Aubele, Simeon Bowers, Darren Dressen, Albert W. Garofalo, Roy K. Hom, Andrei W. Konradi, Jennifer L. Marugg, Matthew N. Mattson, Martin L. Neitzel, Chris M. Semko, Hing L. Sham, Jenifer Smith, Minghua Sun, Anh P. Truong, Xiaocong M. Ye, Ying-zi Xu, Michael S. Dappen, Jacek J. Jagodzinski, Pamela S. Keim, Brian Peterson, Lee H. Latimer, David Quincy, Jing Wu, Erich Goldbach, Daniel K. Ness, Kevin P. Quinn, John-Michael Sauer, Karina Wong, Hongbin Zhang, Wes Zmolek, Elizabeth F. Brigham, Dora Kholodenko, Kang Hu, Grace T. Kwong, Michael Lee, Anna Liao, Ruth N. Motter, Patricia Sacayon, Pamela Santiago, Christopher Willits, Frédérique Bard, Michael P. Bova, Susanna S. Hemphill, Lam Nguyen, Lany Ruslim, Kevin Tanaka, Pearl Tanaka, William Wallace, Ted A. Yednock & Guriqbal S. Basi. (2013) Discovery of ( R )-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1 H -pyrazolo[4,3- c ]quinoline (ELND006) and ( R )-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2 H -pyrazolo[4,3- c ]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch . Journal of Medicinal Chemistry 56:13, pages 5261-5274.
Crossref
Karin G. Haug, Alexander Staab, Chantaratsamon Dansirikul & Thorsten Lehr. (2013) A Semi-Physiological Model of Amyloid-β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development. The Journal of Clinical Pharmacology 53:7, pages 691-698.
Crossref
Harriët Schellekens, Orla McNamara, Timothy G Dinan, Justin V McCarthy, Gerard P McGlacken & John F Cryan. (2013) Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. Journal of Pharmacy and Pharmacology 65:4, pages 528-538.
Crossref
Charles F. Albright, Randy C. Dockens, Jere E. MeredithJr.Jr., Richard E. Olson, Randy Slemmon, Kimberley A. Lentz, Jun-Sheng Wang, R. Rex Denton, Gary Pilcher, Paul W. Rhyne, Joseph J. Raybon, Donna M. Barten, Catherine Burton, Jeremy H. Toyn, Sethu Sankaranarayanan, Craig Polson, Valerie Guss, Randy White, Frank Simutis, Thomas Sanderson, Kevin W. Gillman, John E. StarrettJr.Jr., Joanne Bronson, Oleksandr Sverdlov, Shu-Pang Huang, Lorna Castaneda, Howard Feldman, Vlad Coric, Robert Zaczek, John E. Macor, John Houston, Robert M. Berman & Gary Tong. (2013) Pharmacodynamics of Selective Inhibition of γ -Secretase by Avagacestat . Journal of Pharmacology and Experimental Therapeutics 344:3, pages 686-695.
Crossref
Alessandro Giuliani, Sarah Beggiato, Vito A. Baldassarro, Chiara Mangano, Luciana Giardino, Bruno P. Imbimbo, Tiziana Antonelli, Laura Calzà & Luca Ferraro. (2013) CHF 5074 restores visual memory ability and pre‐synaptic cortical acetylcholine release in pre‐plaque Tg2576 mice . Journal of Neurochemistry 124:5, pages 613-620.
Crossref
Maria C. Carrillo, Christopher C. Rowe, Cassandra Szoeke, Colin L. Masters, David Ames, Tim O'Meara, S. Lance Macaulay, Andrew Milner, Kathryn A. Ellis, Paul Maruff, Stephanie R. Rainey‐Smith, Ralph N. Martins, Lisa J. Bain & Richard J. Head. (2012) Research and standardization in Alzheimer's trials: Reaching international consensus. Alzheimer's & Dementia 9:2, pages 160-168.
Crossref
Timothy D. McKee, Robyn M.B. Loureiro, Jo Ann Dumin, Vladislav Zarayskiy & Barbara Tate. (2013) An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates. Journal of Neuroscience Methods 213:1, pages 14-21.
Crossref
Kevin Mullane & Michael Williams. (2013) Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?. Biochemical Pharmacology 85:3, pages 289-305.
Crossref
Željko M. Svedružić, Katarina Popović & Vesna Šendula-Jengić. (2013) Modulators of γ-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease. PLoS ONE 8:1, pages e50759.
Crossref
Lynn A. Hyde, Qi Zhang, Robert A. Del Vecchio, Prescott T. Leach, Mary E. Cohen-Williams, Lei Chen, Gwendolyn T. Wong, Nansie A. McHugh, Joseph Chen, Guy A. Higgins, Theodros Asberom, Wei Li, Dmitri Pissarnitski, Diane Levitan, Amin A. Nomeir, John W. Clader, Lili Zhang & Eric M. Parker. (2013) In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects. International Journal of Alzheimer's Disease 2013, pages 1-14.
Crossref
Gary Tong, Lorna Castaneda, Jun-Sheng Wang, Oleksandr Sverdlov, Shu-Pang Huang, Randy Slemmon, Huidong Gu, Oi Wong, Hewei Li, Robert M. Berman, Christina Smith, Charles Albright & Randy C. Dockens. (2012) Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men. Clinical Drug Investigation 32:11, pages 761-769.
Crossref
Alexander V. LyubimovIndranil Rao, HK Vinay & Sandhya Mandlekar. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions 1 51 .
Chihiro Tohda, Takuya Urano, Masahito Umezaki, Ilka Nemere & Tomoharu Kuboyama. (2012) Diosgenin is an exogenous activator of 1,25D3-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Scientific Reports 2:1.
Crossref
Salvatore Salomone, Filippo Caraci, Gian Marco Leggio, Julia Fedotova & Filippo Drago. (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology 73:4, pages 504-517.
Crossref
Željko M. Svedružić, Katarina Popović, Ivana Smoljan & Vesna Šendula-Jengić. (2012) Modulation of γ-Secretase Activity by Multiple Enzyme-Substrate Interactions: Implications in Pathogenesis of Alzheimer's Disease. PLoS ONE 7:3, pages e32293.
Crossref
Michael S. Rafii. 2012. Molecular and Cellular Therapeutics. Molecular and Cellular Therapeutics 233 244 .
Yasuyuki Mitani, Junko Yarimizu, Kyoko Saita, Hiroshi Uchino, Hiroki Akashiba, Yoshitsugu Shitaka, Keni Ni & Nobuya Matsuoka. (2012) Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice. The Journal of Neuroscience 32:6, pages 2037-2050.
Crossref
Manel Ben Aissa, Marie-Claude April, Lucien-Junior Bergeron, Jean-Pierre Perreault & Georges Levesque. (2012) Silencing of Amyloid Precursor Protein Expression Using a New Engineered Delta Ribozyme. International Journal of Alzheimer's Disease 2012, pages 1-12.
Crossref
Alena V Savonenko, Tatiana Melnikova, Andrew Hiatt, Tong Li, Paul F Worley, Juan C Troncoso, Phil C Wong & Don L Price. (2011) Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology 37:1, pages 261-277.
Crossref
Kenji Sugimoto, Kosuke Tamura, Naoki Ohta, Chihiro Tohda, Naoki Toyooka, Hideo Nemoto & Yuji Matsuya. (2012) Synthesis of dihydrofuran-fused perhydrophenanthrenes having a phenolic hydroxyl group as a novel anti-Alzheimer’s disease agent. Bioorganic & Medicinal Chemistry Letters 22:1, pages 449-452.
Crossref
Anne Jämsä, Oscar Belda, Michael Edlund & Erik Lindström. (2011) BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells. Journal of Biomedical Science 18:1.
Crossref
Kazuhiro Mochizuki, Shan He & Yi Zhang. (2011) Notch and inflammatory T-cell response: new developments and challenges. Immunotherapy 3:11, pages 1353-1366.
Crossref
Fadi Massoud & Gabriel C Léger. (2011) Pharmacological Treatment of Alzheimer Disease. The Canadian Journal of Psychiatry 56:10, pages 579-588.
Crossref
Il-Jun Kang, Young Eun Jeon, Xing Fu Yin, Jin-Sik Nam, Sang Guan You, Myo Soon Hong, Bong Geom Jang & Min-Ju Kim. (2011) Butanol extract of Ecklonia cava prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. Food and Chemical Toxicology 49:9, pages 2252-2259.
Crossref
Jonathan Kimmelman & Alex John London. (2011) Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty. PLoS Medicine 8:3, pages e1001010.
Crossref
Alexander Kurz & Robert Perneczky. (2011) Novel insights for the treatment of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:2, pages 373-379.
Crossref
Rachelle S. Doody, Patricia E. Cole, David S. Miller, Eric Siemers, Ronald Black, Howard Feldman, Rachel Schindler, Stephen Graham, Theresa Heath, Ara S. Khachaturian, Rebecca Evans & Maria C. Carrillo. (2011) Global issues in drug development for Alzheimer's disease. Alzheimer's & Dementia 7:2, pages 197-207.
Crossref
Gerard J. Marek. 2011. Translational Medicine and Drug Discovery. Translational Medicine and Drug Discovery 168 179 .
Yukihiro Matsunoshita, Kosei Ijiri, Yasuhiro Ishidou, Satoshi Nagano, Takuya Yamamoto, Hiroko Nagao, Setsuro Komiya & Takao Setoguchi. (2011) Suppression of Osteosarcoma Cell Invasion by Chemotherapy Is Mediated by Urokinase Plasminogen Activator Activity via Up-Regulation of EGR1. PLoS ONE 6:1, pages e16234.
Crossref
Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney, Juha Yrjänheikki & Howard M Fillit. (2011) Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimer's Research & Therapy 3:5, pages 28.
Crossref
Jason A. Smith, Peter P. Molesworth, Christopher J.T. Hyland & John H. Ryan. 2011. 491 536 .
Sam Gandy & Brandon Wustman. (2011) New pathway links γ‐secretase to inflammation and memory while sparing notch. Annals of Neurology 69:1, pages 5-7.
Crossref
Huidong Gu, Yuzhong Deng, Jian Wang, Anne-Françoise Aubry & Mark E. Arnold. (2010) Development and validation of sensitive and selective LC–MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. Journal of Chromatography B 878:25, pages 2319-2326.
Crossref
Meaghan C. Creed & Norton W. Milgram. (2010) Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications. AGE 32:3, pages 365-384.
Crossref
Johan Lundkvist & Urban Lendahl. 2010. Aspartic Acid Proteases as Therapeutic Targets. Aspartic Acid Proteases as Therapeutic Targets 325 351 .
Thomas A. Lanz, Kathleen M. Wood, Karl E. G. Richter, Charles E. Nolan, Stacey L. Becker, Nikolay Pozdnyakov, Barbara-Anne Martin, Ping Du, Christine E. Oborski, Douglas E. Wood, Tracy M. Brown, James E. Finley, Sharon A. Sokolowski, Carol D. Hicks, Karen J. Coffman, Kieran F. Geoghegan, Michael A. Brodney, Dane Liston & Barbara Tate. (2010) Pharmacodynamics and Pharmacokinetics of the γ-Secretase Inhibitor PF-3084014. Journal of Pharmacology and Experimental Therapeutics 334:1, pages 269-277.
Crossref
Francesca Mangialasche, Alina Solomon, Bengt Winblad, Patrizia Mecocci & Miia Kivipelto. (2010) Alzheimer's disease: clinical trials and drug development. The Lancet Neurology 9:7, pages 702-716.
Crossref
Manuela Bartolini & Vincenza Andrisano. (2010) Strategies for the Inhibition of Protein Aggregation in Human Diseases. ChemBioChem 11:8, pages 1018-1035.
Crossref
Ola Philipson, Anna Lord, Astrid Gumucio, Paul O’Callaghan, Lars Lannfelt & Lars N.G. Nilsson. (2010) Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease. The FEBS Journal 277:6, pages 1389-1409.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.